On May 28, 2025 Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported that CFO Raphi Levy will present at the Jefferies Global Healthcare Conference on June 5, 2025 (Press release, Alpha Tau Medical, MAY 28, 2025, View Source [SID1234653428]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Jefferies Global Healthcare Conference
Format: Presentation
Date: June 5, 2025
Time: 1:25 – 1:55PM ET
Location: New York, NY

Mr. Levy will be available for 1×1 investor meetings. Please reach out to your Jefferies representative to schedule.

On May 28, 2025 Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, reported that its management team is scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 8:40 a.m. ET (Press release, Agios Pharmaceuticals, MAY 28, 2025, View Source [SID1234653427]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

On May 28, 2025 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, reported that the Company will participate in two upcoming healthcare conferences in June (Press release, Aclaris Therapeutics, MAY 28, 2025, View Source [SID1234653426]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Wednesday June 4, 2025, at 10:30 AM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during Jefferies Global Healthcare Conference in New York, NY.

On Wednesday June 11, 2025, at 1:20 PM EDT, Dr. Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, FL.
A live and archived webcast of both events will be accessible on the Events page of View Source The webcasts will be available on the Aclaris website for at least 30 days.

On May 27, 2025 BetaGlue Therapeutics S.p.A. ("BetaGlue"), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose, reported that an abstract was published by the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) entitled: "Preclinical study of safety and efficacy in vivo of a yttrium-90 resin microspheres glue formulation in a large animal model of pancreatic cancer."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract describes the use of YntraDose to treat orthotopic tumors in an advanced in vivo porcine model called ‘oncopig’. Five animals were treated and followed-up over 30 days, the findings were:

No adverse events were reported throughout the study period;
YntraDose implantation and its associated radiotherapeutic payload were confined to the site of administration as demonstrated by radiological PET/CT assessment; and
At 30days visual necropsy assessment not only revealed evidence of tumor necrosis but also indicated tumor debulking.
Dr Colin Story, CEO, BetaGlue Therapeutics commented: "This study utilised a cutting edge advanced large animal model of pancreatic cancer where procedures were performed by world-renowned Interventional Radiologist and key opinion leader Professor Govindarajan Narayanan. BetaGlue is focused on bringing YntraDose to patients that present with Locally-Advanced Pancreatic Cancer which by definition is inoperable. We are very grateful to our collaborators Prof. Narayanan, Dr Geschwind and Ms Felicia Bealo for their contribution to this work."

Professor Govindarajan Narayanan, Chief of Interventional Oncology for the Miami Cancer Institute and lead author of the abstract commented: "Locally-Advanced Pancreatic Cancer (LAPC) accounts for around 30% of all Pancreatic Cancers worldwide. This study provides preliminary evidence of the utility for YntraDose as a local treatment option for LAPC with the potential to down-stage patients and enabling surgical resection to take place."

(Press release, BetaGlue Therapeutics, MAY 27, 2025, View Source [SID1234661239])

On May 27, 2025 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, reported a debt financing agreement for up to USD 262.5 million from funds managed by Blue Owl Capital, Inc ("Blue Owl"). The capital will be used to prepare for commercial readiness and potential market launch of the company’s lead candidate, n.c.a.177Lu-edotreotide (also known as ITM-11 or177Lu-edotreotide). ITM-11 recently met the primary endpoint in the COMPETEPhase 3 study as a potential treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM plans to submit a New Drug Application (NDA) for this asset to the U.S. FDA in 2025. In addition, the company will continue to accelerate the development of its innovative targeted radiopharmaceutical pipeline and the scale-up of Actinium-225 manufacturing through its joint venture, Actineer. Under the terms of the agreement, ITM will receive USD 140 million upon closing and can exercise additional tranches. Further details of the agreement have not been disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Blue Owl is a highly regarded investor with a deep appreciation for the potential of radiopharmaceuticals, and we see their debt capital for ITM as a validation of our position as a cornerstone of the radiopharmaceutical industry," said Dr. Andrew Cavey, CEO of ITM. "This strategic funding agreement enables us to move rapidly toward the potential U.S. commercialization of ITM-11, subject to FDA approval, and provides flexibility for the development and expansion of our innovative pipeline of targeted radiopharmaceuticals across a broad range of indications."

"With its vertically integrated approach that combines a profitable radioisotope manufacturing business with radiopharmaceutical pipeline development, we believe ITM is uniquely positioned to positively impact the precision oncology sector. We look forward to supporting ITM’s continued growth and mission to bring innovative treatment options to people living with cancer," said Sandip Agarwala, Managing Director and Head of Life Sciences at Blue Owl.

About n.c.a.177Lu-edotreotide (ITM-11)
177Lu-edotreotide is a radiolabeled peptide conjugate that delivers beta radiation specifically to SSTR-positive tumor cells, sparing healthy organs and tissue. The drug candidate, delivered intravenously, is comprised of non-carrier-added Lutetium-177, a therapeutic β-emitting radioisotope, and edotreotide, a synthetic SSTR agonist. 177Lu-edotreotide was granted orphan drug designation in the E.U. and the U.S., and fast track designation in the U.S. for the treatment of GEP-NETs, based on positive results from a retrospective Phase 2 study with177Lu-edotreotide.

(Press release, ITM Isotopen Technologien Munchen, MAY 27, 2025, View Source [SID1234661160])